Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb;10(Suppl 1):19-23.
doi: 10.1007/s13193-019-00874-0. Epub 2019 Jan 16.

Treatment of Peritoneal Surface Malignancies with Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC): Experience in Israel

Almog Ben-Yaacov  1 , Eran Nizri  2 , Guy Lahat  2 , Yaniv Berger  3 , Eran Sadot  4 , Ron Lavi  5 , Dov Zippel  1 , Gilbert Sebbag  6 , Itzhak Avital  6 , Aviad Hoffman  7 , Mordechai Gutman  3 , Ariel Halevy  5 , Shlomo Schneibaum  2 , Gur Ben-Ari  1 , Daniel Benchimol  4 , Joseph Klausner #  2 , Aviram Nissan #  1 ; Israeli Peritoneal Oncology Research Group
Affiliations

Treatment of Peritoneal Surface Malignancies with Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC): Experience in Israel

Almog Ben-Yaacov et al. Indian J Surg Oncol. 2019 Feb.

Abstract

The treatment of peritoneal surface malignancies, either primary or secondary (peritoneal metastasis), has evolved over the past two decades. A nihilistic approach of incurable "carcinomatosis" is changing into treatment of peritoneal metastasis with curative intent. The aim of the present study is to review the current practice, past history, and future of peritoneal surface oncology in Israel. A systematic review of all patients treated in institutions performing cytoreductive surgery (CRS) and hyperthermic intra-peritoneal chemotherapy (HIPEC) for the treatment of peritoneal surface malignancies. Each center provided the following data: start year, number of total cases, number of cases performed in 2017, and the method used (open vs. closed technique). Between 1990 and 2018, there were 1462 patients treated by CRS/HIPEC in Israel by eight different surgical groups in six medical centers. Currently, there are seven surgical groups in six medical centers routinely performing CRS/HIPEC. The annual rate of CRS/HIPEC was 171 cases in 2017 with a range of (4-69 cases/center). This is the first step of establishing an Israeli Peritoneal Surface Oncology Group that will have joined database and perform clinical trials in this challenging field of surgical oncology.

Keywords: Cytoreductive surgery; Experiance in Israel; Hyperthermic intraperitoneal chemotherapy; Multiple center experiance; Peritoneal surface malignancy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Origin of PSM treated in 2017 (n = 171)
See this image and copyright information in PMC

References

    1. Passot G, Vaudoyer D, Villeneuve L, Kepenekian V, Beaujard AC, Bakrin N, Cotte E, Gilly FN, Glehen O. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures. J Surg Oncol. 2016;113(7):796–803. doi: 10.1002/jso.24248. - DOI - PubMed
    1. Spratt JS, Adcock RA, Muskovin M, Sherrill W. McKeown J. clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40(2):256–260. - PubMed
    1. Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin N Am. 2003;12:703–727. doi: 10.1016/S1055-3207(03)00048-6. - DOI - PubMed
    1. Mehta SS, Bhatt A, Glehen O. Cytoreductive surgery and peritonectomy procedures. Indian J Surg Oncol. 2016;7(2):139–151. doi: 10.1007/s13193-016-0505-5. - DOI - PMC - PubMed
    1. Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K, Morris DL. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–2456. doi: 10.1200/JCO.2011.39.7166. - DOI - PubMed

LinkOut - more resources